NSCLC is the most common type of lung cancer. About 80 to 85% of all lung carcinomas are NSCLC.

Stage 4 indicates the cancer has spread to distant tissues.

NSCLC stage 4 has a 5-year relative survival rate of 12%.

Relative survival rate is the percentage of people who will still be alive a specific number of years after diagnosis compared with the rest of the population. In the example above, this time period is 5 years.

However, it’s important to note these figures are based on past data, and current survival rates are likely higher than this due to medical advancements.

The 5-year relative survival rate of 12% also does not represent your individual life expectancy, as this is dependent on multiple factors unique to you and your treatment.

Discussing your individual cancer and other health factors with your medical team will give you greater insight into your personal outlook. Your team can assess your specific situation and offer you tailored advice to give you the best possible chance.

According to the American Cancer Society, treatment for stage 4 NSCLC can vary, depending on your overall health. You may be given more types of chemo drugs at a time if your body can handle it. If you are unable to have chemo, you may have radiation therapy instead.

Other local treatments can include:

  • laser therapy
  • photodynamic therapy
  • stent placement

Your medical team may also suggest you take part in a clinical trial for newer treatments to improve your outlook further.